Weight‑loss drugs such as Wegovy and Ozempic have transformed obesity treatment, but a former Novo Nordisk scientist says a diet overhaul could trigger the same hormone, GLP‑1, without a needle. Dr. Anette Sams, who helped develop semaglutide, outlines how gut‑derived hormones can be boosted naturally, offering a cheaper, needle‑free alternative.

Dr. Anette Sams' 15‑year GLP‑1 research at Novo Nordisk

During a 15‑year stint that ended in 2015, Dr. Sams led research on blood sugar, type‑2 diabetes, gut hormones and inflammation at Novo Nordisk, the maker of Wegovy and Ozempic.. according to the source, she was directly involved in the GLP‑1 work that later produced semaglutide, a synthetic version of the body’s own glucagon‑like peptide‑1.

Her background gives her a unique perspective on the trade‑off between pharmaceutical potency and the long‑term sustainability of lifestyle‑based solutions .

How L‑cells along the 26‑foot gut trigger natural GLP‑1

L‑cells are specialized sensor cells that line the 26‑foot‑long gastrointestinal tract, detecting nutrients and releasing hormones such as GLP‑1, PYY and GLP‑2. The source notes that these cells are unevenly distributed, making certain dietary patterns especially effective at stimulating hormone release.

When nutrients reach the L‑cells, they send signals to the bloodstream that can curb appetite, improve glucose control and lower the risk of cardiovascular disease—effects that mirror those of injectable GLP‑1 analogues.

Dietary shifts that could replace semaglutide injections

Dr. Sams recommends dramatically increasing vegetable intake while cutting ultra‑processed foods to activate L‑cells. She describes this not as a restrictive “No‑Zempic” diet but as a holistic approach aimed at overall physical and mental health.

By feeding the gut with fiber‑rich, low‑glycemic foods, individuals may naturally raise GLP‑1 levels at a fraction of the cost of weekly injections, according to the report.

Who is demanding Wegovy beyond clinical need

Clinicians are seeing a surge of patients—some confrontational—seeking prescriptions for Wegovy even when they do not meet obesity criteria. The source highlights the ethical tension between genuine medical necessity and the desire to emulate peers who have accessed the drugs .

This demand underscores why alternative, non‑pharmaceutical pathways are gaining attention among both doctors and policymakers.

Is the diet‑only approach clinically proven?

The article does not cite large‑scale trials confirming that diet alone can match the weight‑loss magnitude of semaglutide. As a result, the scientific community still lacks definitive evidence on long‑term outcomes, and Dr. sams’ proposal remains a hypothesis awaiting rigorous testing.

Further research will need to compare hormone levels,weight trajectories and health markers between diet‑induced GLP‑1 activation and pharmaceutical analogues.